CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 118,440	$ 12,821
Accounts receivable	62,694	60,427
Inventories	6,829	7,474
Other current assets	6,307	5,153
Total current assets	194,270	85,875
Property and equipment (net of accumulated depreciation of $49,492 and $40,530, respectively)	41,004	36,504
Intangible assets, net	69,909	74,165
Goodwill	147,019	147,019
Other assets	2,937	891
Total assets	455,139	344,454
Current liabilities
Accounts payable	9,200	10,450
Accrued compensation	15,187	9,482
Accrued expenses and other liabilities	7,517	6,144
Short-term portion of capital leases and car loans	6,675	5,239
Short-term portion of loans	7,217	3,750
Pharma contract liability	1,259	1,406
Total current liabilities	47,055	36,471
Long-term liabilities
Long-term portion of capital leases and car loans	6,663	5,303
Long-term portion of loans, net	89,764	66,616
Revolving credit facility, net	0	24,516
Long-term pharma contract liability	1,199	283
Deferred income tax liability, net	6,899	6,688
Total long-term liabilities	104,525	103,406
Total liabilities	151,580	139,877
Commitments and contingencies - see Note I
Redeemable convertible preferred stock
Series A Redeemable Convertible Preferred Stock, $0.001 par value, (50,000,000 shares authorized; 0 and 6,864,000 shares issued and outstanding)	0	32,615
Stockholders' equity
Common stock, $0.001 par value, (250,000,000 shares authorized; 92,980,783 and 80,462,574 shares issued and outstanding, respectively)	93	80
Additional paid-in capital	354,487	230,030
Accumulated other comprehensive income	536	274
Accumulated deficit	(51,557)	(58,422)
Total stockholders’ equity	303,559	171,962
Total Liabilities and Stockholders' Equity	$ 455,139	$ 344,454